SPOTLIGHT: Bristol-Myers pulls assets from Ireland


Bristol-Myers Squibb is pulling $25 billion in assets out of its Irish holding company. An Irish Times report said that BMS was being dispatched to another country with an even lower corporate tax rate than Ireland's. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.